CN109646591B

CN109646591B - Composition for oral cavity and application thereof

Info

Publication number: CN109646591B
Application number: CN201910022612.3A
Authority: CN
Inventors: 郭智华; 徐双华; 尚林晏
Original assignee: Hongle Health Shenzhen Co ltd
Current assignee: Qianhuatang Health Technology China Co ltd
Priority date: 2019-01-10
Filing date: 2019-01-10
Publication date: 2022-02-01
Anticipated expiration: 2039-01-10
Also published as: CN109646591A

Abstract

The invention relates to a composition for oral cavity and application thereof. The composition comprises the following active components in parts by weight: 0.01-10 parts of purple bamboo salt; 0.01-15 parts of dragon's blood extract; 0.01-12 parts by weight of latanib extract. The oral product provided by the invention not only can clean the oral cavity, but also can relieve gingivitis, stop bleeding, relieve swelling, relieve toothache, eliminate halitosis and oral ulcer, and basically has no adverse reaction.

Description

Composition for oral cavity and application thereof

Technical Field

The invention relates to the technical field of daily chemical products, in particular to a composition with an oral health function and an application and a preparation method thereof.

Background

Oral health is one of ten major standards of human health established by the world health organization. Oral health and whole body health are a close and inseparable whole body. With the increasing living standard of Chinese people, the oral health problem is concerned by more people. The third national oral health epidemiological survey shows that 97% of adults in China are troubled by different oral problems, and seven prominent oral problems are listed: including caries, tartar, plaque, gingival bleeding, dentin sensitivity, unclean and white teeth, bad breath.

Bleeding of the gums, often as a result of gingivitis, occurs. Gingivitis is the result of the stimulation of tartar and tartar; the formation of tartar and tartar is caused by the inability to frequently remove the food debris and calcium that has accumulated in the crevices and pockets completely. Inflamed roots are deep red, edematous, prone to bleeding on touch, and can also be caused by improper use of toothbrushes.

Oral malodour is mainly caused by the proliferation of bacteria in the oral cavity, and some oral malodour is considered to be related to certain diseases. In the oral cavity, the known bacterial species can be more than 700, and the oral cavity can be kept in a healthy state only by keeping good ecological balance among microorganisms in the oral cavity and between the microorganisms and host oral cavity tissues.

When the teeth are stimulated by cold, heat, acid, sweet and mechanical action (rubbing, biting), a sensation of soreness is suddenly produced, or it is flashed off, or it is briefly sustained, which sensation of soreness disappears when the stimulus is removed.

The oral ulcer, also called as aphtha, is superficial ulcer on oral mucosa, can be from rice grain to soybean in size, and is circular or oval, and ulcer surface is depression and peripheral hyperemia of oral ulcer, can cause pain due to irritant food, and can be self-healed generally for one to two weeks. Some people are susceptible to recurrent oral ulcer, and the specific pathogenesis is not clear in western medicine clinical research. The traditional Chinese medicine considers that the recurrent oral ulcer is caused by excessive heat and toxic fire, impairment of yin qi and deficiency of vital qi and can not expel toxin. For treatment, it should be used to tonify qi, remove toxicity, heal wound and promote granulation.

The above problems bring certain troubles to the oral health of people and bring adverse effects to our lives.

Disclosure of Invention

In order to solve the problems, the invention provides an oral product which not only can clean the oral cavity, but also can relieve gingivitis, stop bleeding, relieve swelling, relieve toothache, eliminate halitosis and oral ulcer, and basically has no adverse reaction.

The invention is realized by adopting the following technical scheme.

A composition for oral cavity comprises the following active components in parts by weight:

0.01-10 parts of purple bamboo salt;

0.01-15 parts of dragon's blood extract;

0.01-12 parts by weight of latanib extract.

Preferably, the composition for oral cavity comprises the following active components in parts by weight:

0.1-5 parts of purple bamboo salt;

0.1-5 parts of dragon's blood extract;

0.5-5 parts by weight of latanib extract.

Further research shows that in the composition for oral cavity, the active components comprise the purple bamboo salt, the dragon's blood extract and the latanib extract, the mass ratio of the purple bamboo salt to the dragon's blood extract to the latanib extract is 1 (1-5) to 0.5-7, and particularly, the synergistic effect is better when the mass ratio of the purple bamboo salt to the dragon's blood extract to the latanib extract is 1 (1.2-3) to (1-2.5).

In some embodiments of the present invention, in the composition for oral cavity, the mass ratio of the salt of black bamboo, the dragon's blood extract and the latanib extract is 1:5:7, 1:3:0.5, 1:2.5:2.5, 1:1.2:1, respectively.

The purple bamboo salt has a long history of preparation and application, and has the effects of resisting bacteria, diminishing inflammation, expelling toxin, beautifying and the like. The purple bamboo salt can be prepared by adopting the prior art or purchased in the market.

In some embodiments of the invention, the purple bamboo salt is prepared by filling salt into a bamboo tube, and calcining and extracting the salt for nine times at high temperature, and has better effects of resisting bacteria and diminishing inflammation, expelling toxin, beautifying and the like.

In some embodiments of the present invention, the purple bamboo salt is prepared as follows: filling salt into green bamboo tube, and sealing with clay. The bamboo tube is put into a furnace and calcined by pine at the high temperature of 1500 ℃ and 1000 ℃. The salt column after 8 hours of calcination was ground to a powder and calcined again and repeated 8 times. The column was placed in the oven at 9 th time and heated to above 1300 ℃ with a turpentine fire. Melting salt, pouring into a bowl, and cooling to obtain the final product.

Sanguis Draxonis (Draconis Sanguis) is resin exuded from fruit of Daemonorops draco Bl (Palmaceae), and is widely used as traditional and rare medicinal material worldwide. The dragon's blood has stronger antibacterial, anti-inflammatory and anti-tumor activities and the treatment effects of hemostasis, anti-thrombosis and the like. Dracorhodin is an important active ingredient of dragon's blood.

The dragon's blood extract is prepared by extracting and refining resin of daemonorops draco of Palmae and plants in the same genus. The dragon's blood has the reputation of the holy medicine for promoting blood circulation, has mild nature, sweet, warm, salty and mild taste, and is suitable for heart and liver meridians, and has the functions of promoting blood circulation, removing blood stasis, relieving pain, stopping bleeding, resisting bacteria, resisting tumors, enhancing immunity, reducing blood sugar, resisting inflammation, promoting epidermis repair and the like.

The roots of ratanhy described in the present invention have been used since ancient times by peru in the treatment of oral inflammation and injury. The latanib extract of the present invention is an alcoholic extract obtained from the roots of plants. Can be prepared according to the prior art. The ratanhia root extract is rich in benzofuran, ellagitannin and protocatechuic tannin, and can inhibit reproduction of various microorganisms, especially gram positive bacteria and fungi.

Preferably, the active ingredient of the composition further comprises an echinacea extract, which is added to the composition in an amount of preferably 0.01 to 5 parts by weight, more preferably 0.1 to 3 parts by weight. The invention surprisingly finds that the addition of the echinacea purpurea extract in the composition can further obviously improve the curative effect of the composition.

The Echinacea extract (Echinacea Herb P.E) is obtained by extracting whole plant of Echinacea purpurea (Echinacea purpurea) belonging to Compositae. The product is yellowish green powder, has slightly astringent taste, has natural fragrance of Echinacea, is soluble in water and diluted ethanol, and contains Echinacea polyphenol as main ingredient. At present, the echinacea purpurea extract can stimulate immune response, strengthen an immune system, prevent influenza, shorten the period of catching a cold by cold, assist in treating arthritis or skin diseases, promote wound healing, relieve toothache and pain caused by burns and scalds, resist bacterial and viral infection and assist in treating cancers, is greatly concerned at home and abroad, and is widely applied to medicines, nutritional supplements and health-care foods in Europe and America at present.

further research shows that in the composition for oral cavity, the active components comprise the purple bamboo salt, the dragon's blood extract, the latanib extract and the echinacea extract, the mass ratio of the purple bamboo salt, the dragon's blood extract, the latanib extract and the echinacea extract is 1 (0.1-8) to (1-2) to (0.1-6), preferably 1 (0.1-0.5) to (1.2-1.5) to (0.2-0.5), and the synergistic effect is better.

In some embodiments of the invention, the mass ratio of the salt of black bamboo, the dragon's blood extract, the latania extract and the echinacea extract is 1:8:1:6, 1:0.1:1.2:0.2, 3:0.5:4:1, 1:0.5:1.25:0.25, respectively.

The invention also provides application of the composition in any one of the technical schemes in preparation of a medicine or an oral care product for cleaning oral cavity, relieving gingivitis, stopping bleeding, relieving swelling, relieving toothache, removing halitosis or treating oral ulcer. Wherein the oral care product comprises toothpaste, mouthwash, tooth powder, oral spray, oral ointment and the like.

The medicine or the oral care product takes the composition obtained by any one of the technical schemes as an active component.

Specifically, the invention provides toothpaste which comprises the following components in parts by weight:

active component

0.01-10 parts of purple bamboo salt;

0.01-15 parts of dragon's blood extract;

0.01-12 parts by weight of latanib extract;

auxiliary materials

Preferably, the mass ratio of the purple bamboo salt, the dragon's blood extract and the latania extract in the toothpaste is 1 (1-5) to (0.5-7), and more preferably 1 (1.2-3) to (1-2.5).

Specifically, the invention also provides another toothpaste which comprises the following components in parts by weight:

active component

Auxiliary materials

In the toothpaste, the mass ratio of the purple bamboo salt, the dragon blood extract, the latania extract and the echinacea extract is preferably 1 (0.1-8) to (1-2) to (0.1-6), more preferably 1 (0.1-0.5) to (1.2-1.5) to (0.2-0.5).

The abrasive is selected from one or more of silicon dioxide, hydrated calcium hydrophosphate, anhydrous calcium hydrophosphate, calcium carbonate, aluminum hydroxide, sodium chloride or calcium pyrophosphate;

the humectant is selected from one or more of sorbitol, glycerol, propylene glycol, polyethylene glycol-8 or butanediol;

the foaming agent is selected from one or more of sodium dodecyl sulfate, sodium lauroyl sarcosinate, sodium cocoyl glycinate, sodium acyl glutamate or sodium cocoyl methyl taurate;

the thickening agent is selected from one or more of cellulose and derivatives thereof, guar gum, sodium alginate, xanthan gum, guar gum hydroxypropyl trimethyl ammonium chloride, carrageenan or locust bean;

the sweetener is selected from one or more of saccharin sodium, sucralose, xylitol, sodium cyclamate, aspartame, stevioside or mogroside;

the essence is selected from one or more of vanilla essence, spearmint essence, mint essence or wintergreen mint essence;

the preservative is selected from one or more of benzoic acid and salts thereof, sorbic acid and salts thereof or parabens;

the appearance modifier is selected from one or more of titanium dioxide, food pigment, food color lake or tooth cleaning particle;

the solvent is selected from deionized water.

The invention also provides a preparation method of the toothpaste, which comprises the following steps: mixing the above active components (composition) with adjuvants, and making toothpaste.

The preparation method of the toothpaste comprises the following steps:

A. dissolving the active component in a humectant, and stirring at high speed to prepare a first mixed solution;

B. adding a thickening agent into the first mixed solution, and stirring to obtain a second mixed solution;

C. adding an appearance modifier into the second mixed solution, and stirring to obtain a third mixed solution;

D. adding the third mixed solution, the sweetening agent, the friction agent, the essence, the foaming agent and the preservative into the solvent, and stirring to obtain a fourth mixed solution;

E. continuously stirring the fourth mixed solution under the vacuum condition of 0.08-0.12MPa to prepare paste;

F. checking, aseptically filling into aluminum plastic composite tube, sealing, and making into toothpaste.

The invention also provides mouthwash which comprises the following components in parts by weight:

active component

0.01-10 parts of purple bamboo salt;

0.01-15 parts of dragon's blood extract;

0.01-12 parts by weight of latanib extract;

auxiliary materials

Preferably, the mass ratio of the purple bamboo salt, the dragon's blood extract and the latania extract in the mouthwash is 1 (1-5) to 0.5-7, and more preferably 1 (1.2-3) to 1-2.5.

Specifically, the invention also provides another mouthwash which comprises the following components in parts by weight:

active component

Auxiliary materials

In the mouthwash, the mass ratio of the purple bamboo salt, the dragon blood extract, the latania extract and the echinacea extract is preferably 1 (0.1-8) to (1-2) to (0.1-6), more preferably 1 (0.1-0.5) to (1.2-1.5) to (0.2-0.5).

The solvent is selected from deionized water;

the humectant is selected from one or more of sorbitol, propylene glycol, glycerol and polyethylene glycol-8;

the surfactant is selected from one or more of poloxamer 407, sodium lauryl sulfate, sodium lauroyl sarcosinate and sodium cocoyl methyl taurate;

the thickening agent is selected from one or more of cellulose, carbomer and carrageenan;

the edible essence is selected from one or more of flos Caryophylli, cortex Cinnamomi, flos Osmanthi Fragrantis, oleum Menthae Dementholatum, herb Hierochloes Adoratae essence, herba Menthae Rotundifoliae, herba Menthae Haplocalycis, and herba Menthae Dementholati;

the colorant is selected from one or more of green, blue and red.

Surprisingly, it has been found that the efficacy of the composition of the present invention in terms of antibacterial and anti-inflammatory properties is significantly superior to that of a single component or a combination of several components, and that it shows an excellent synergistic effect, which cannot be predicted based on prior experience, in terms of oral care.

The technical scheme of the invention has the following beneficial effects:

the invention utilizes different medicinal mechanisms of each component, fully exerts the synergistic interaction effect among the components, ensures that the obtained composition can prevent and assist the treatment of oral ulcer, relieve gingivitis and toothache and simultaneously remove halitosis, has safe materials and is suitable for production.

Detailed Description

The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.

The purple bamboo salt used in the following examples and comparative examples was a mannosan salt available from Koreasalt corporation.

The sanguis Draxonis extract used in the following examples and comparative examples is an aqueous extract of sanguis Draxonis (1:60) obtained from Beijing Chengzhen Xin Yuan science and technology development Co., Ltd.

The Ratanhiae extract used in the following examples and comparative examples was Ratanhiae ethanol (63%) extract, available from IREL corporation as Ratanhiae tinctora.

The echinacea extracts used in the following examples and comparative examples were aqueous echinacea extracts obtained from beijing honesty-friendly scientific and technological development ltd.

Example 1

The composition comprises the following components in parts by weight:

0.1 part of purple bamboo salt,

0.5 part of dragon's blood extract,

0.7 part of latanib extract.

Example 2

The composition comprises the following components in parts by weight:

2 parts of purple bamboo salt, namely 2 parts of purple bamboo salt,

6 parts of a dragon's blood extract,

1 part of latanib extract.

Example 3

The composition comprises the following components in parts by weight:

0.8 part of purple bamboo salt,

2 parts of dragon's blood extract.

2 parts of latanib extract.

Example 4

The composition comprises the following components in parts by weight:

10 parts of purple bamboo salt, namely 10 parts of purple bamboo salt,

12 parts of a dragon's blood extract,

10 parts of latanib extract.

Example 5

The composition comprises the following components in parts by weight:

example 6

The composition comprises the following components in parts by weight:

example 7

The composition comprises the following components in parts by weight:

example 8

The composition comprises the following components in parts by weight:

example 9

The toothpaste comprises 100 parts of the following components in parts by weight:

example 10

example 11

example 12

example 13

example 14

example 15

example 16

example 17

The mouthwash with the total weight of 100 parts comprises the following components in parts by weight:

example 18

example 19

example 20

comparative example 1

The composition comprises the following components in parts by weight:

3 parts of a dragon's blood extract,

2 parts of latanib extract.

Comparative example 2

The composition comprises the following components in parts by weight:

2 parts of purple bamboo salt, namely 2 parts of purple bamboo salt,

4 parts of a dragon's blood extract,

3 parts of echinacea purpurea extract.

Comparative example 3

The composition comprises the following components in parts by weight:

3 parts of purple bamboo salt, namely 3 parts of purple bamboo salt,

4 parts of a latanib extract, namely latanib,

2 parts of echinacea purpurea extract.

Comparative example 4

The composition comprises the following components in parts by weight:

2 parts of a dragon's blood extract,

3 parts of a latanib extract, namely latanib,

4 parts of echinacea purpurea extract.

Comparative example 5

comparative example 6

comparative example 7

comparative example 8

comparative example 9

comparative example 10

comparative example 11

experimental example 1 human body test (treatment effect on gingivitis)

(1) Subjects included criteria:

a. the health condition of the whole body is good, and no important systemic diseases of the whole body exist; the number of the remaining teeth in the mouth is more than or equal to 16;

b. the age is 18-65 years old; the nature is not limited;

c, no other medicine is used within 1 month, and the patient does not receive the periodontal disease treatment within 3 months;

d. other similar experimental studies were not simultaneously attended;

e. daily tooth brushing habit (brushing teeth 2 times a day);

f. no other oral hygiene cleaning was performed during the study except for oral cleaning using the toothpaste and toothbrush provided by the study;

g. teeth were consented to be cleaned and no non-emergency dental treatment was performed during the study.

Subject exclusion criteria:

a. not agreeing to the test scheme, and not filling in an informed consent;

b. pregnancy or lactation;

c. systemic diseases such as apoplexy, tuberculosis, diabetes, epilepsy, infectious diseases (such as hepatitis), drug abuse, allergy to toothpaste and other oral hygiene products;

d. there are untreated caries, mucosal disease, pericoronitis.

e. Long-term antibiotic therapy;

f. wearing orthodontic band rings, partial or complete removable dentures, and the bridge prosthesis exceeds 4 natural teeth;

g. there are severe oral lesions: caries, periodontal disease, precancerous lesions, oral inflammatory conditions;

h. are participating in other studies.

(2) The experimental method comprises the following steps:

the experimental subjects participated in the human body trial test of the toothpaste, and the experimental samples were randomly grouped into 25 persons each, and the toothpastes in the examples and the comparative examples were used for each group. The medicine is administered once a day, in the morning and at night, for 12 weeks. The gingivitis status of the subjects was re-evaluated at week 6 and week 12, respectively, following the procedure of baseline examination, adverse reactions were registered and relevant data were retrieved.

(3) The criteria for therapeutic effect are as follows:

and (3) curing: the subjective symptoms of the patient disappear, the gingival inflammation disappears completely, the damaged gingival connective tissue can see new collagen fibers, and the function, color, shape and quality of the gingiva are all recovered to be normal;

improvement: the patient's gingiva and gingival papilla are reddish, have slight edema, hyperemia, and are brittle, and have little punctate bleeding when the gingival sulcus is touched by a blunt round probe;

and (4) invalidation: the patient's gingiva still had swelling and pain, and bleeding was seen in probing without improvement of symptoms and signs.

The total effective rate of treatment is (cure + improvement)/total number of cases is multiplied by 100%.

(4) The results are given in the following table:

EXAMPLE 2 human test (treatment effect on gingivitis)

(1) Subject inclusion and exclusion criteria were the same as in example 1.

(2) The experimental method is the same as that of experimental example 1:

(3) the criteria for determining the therapeutic effect were the same as in experimental example 1.

(4) The results are given in the following table:

	cure (example)	Improvement (example)	Invalid (example)	Effective rate (%)
					Comparative example 8	2	8	15	40
Comparative example 9	5	9	11	56
					Comparative example 10	4	8	13	48
Comparative example 11	4	9	12	52
					Example 13	11	10	4	84
Example 14	14	9	2	92
					Example 15	11	11	3	88
Example 16	12	10	3	88

EXAMPLE 3 human body test (treatment of toothache)

(1) Subject inclusion and exclusion criteria were the same as in example 1.

(2) The experimental method comprises the following steps:

the experimental subjects participated in the human body trial test of the toothpaste, and the experimental samples were randomly grouped into 25 persons each, and the toothpastes in the examples and the comparative examples were used for each group. The composition is administered once a day, in the morning and at night, and the subjects are re-evaluated after 2 weeks of continuous use, adverse reactions are registered, and relevant data are retrieved.

(3) And (3) evaluating the effect:

and (3) curing: the toothache symptoms disappeared and did not recur after 2 weeks of treatment.

The effect is shown: the pain degree and the attack frequency of the toothache during attack are obviously reduced compared with those before treatment.

And (4) invalidation: the toothache of patients is not changed or worsened before and after treatment.

The total effective rate of treatment is (cure + significant) cases/total cases x 100%.

(4) The results are given in the following table:

	cure (example)	Improvement (example)	Invalid (example)	Effective rate (%)
					Comparative example 5	2	5	18	28
Comparative example 6	0	6	19	24
					Comparative example 7	0	5	20	20
Example 9	2	10	13	48
					Example 10	4	8	13	48
Example 11	5	8	12	52
					Example 12	3	7	15	40

EXAMPLE 4 human body test (treatment of toothache)

(1) Subject inclusion and exclusion criteria were the same as in example 1.

(2) The experimental procedure was the same as in example 3.

(3) The evaluation criteria for the effects were the same as in example 3.

(4) The results are given in the following table:

	cure (example)	Improvement (example)	Invalid (example)	Effective rate (%)
					Comparative example 8	1	7	17	32
Comparative example 9	2	8	15	40
					Comparative example 10	1	8	16	36
Comparative example 11	1	8	16	36
					Example 13	8	7	10	60
Example 14	10	11	4	84
					Example 15	9	8	8	68
Example 16	9	11	5	80

EXAMPLE 5 human test (treatment effect on halitosis)

(1) Subject inclusion and exclusion criteria were the same as in example 1.

(2) The experimental method comprises the following steps:

the experimental subjects participated in the human body trial test of the toothpaste, and the experimental samples were randomly grouped into 25 persons each, and the toothpastes in the examples and the comparative examples were used for each group. The oral cavity air-conditioning agent is used once in the morning and at night every day, and after being used for 30 days continuously, a subject is checked for oral cavity air values, adverse reactions are registered, and relevant data are retrieved.

(3) And (3) evaluating the effect:

20-28 hours before each clinical examination (evening before examination and morning before examination), all oral cavity cleaning measures are stopped, and normal diet is carried out. Each examination was scheduled at 8:30-11:00 a.m. Breath values were checked for each visit.

Halitosis scoring the scoring protocol of Rosenberg was used, as follows:

0 point, no halitosis, and definitely no odor.

Score 1, suspected bad breath, similar to an audible smell.

2 points, slight halitosis, definitely smells bad smell, but very slight.

Score 3, moderate halitosis, obvious halitosis.

4 points, severe halitosis, but it is barely tolerated by the examiners.

5 points out strong odor, which is intolerable to the examiners.

(4) The results are given in the following table:

	before use	After use
			Comparative example 5	4.45	4.12
Comparative example 6	4.35	4.03
			Comparative example 7	4.42	4.07
Example 9	4.37	2.89
			Example 10	4.43	2.96
Example 11	4.39	2.84
			Example 12	4.41	2.98

EXAMPLE 6 human test (treatment effect on halitosis)

(1) Subject inclusion and exclusion criteria were the same as in example 1.

(2) The experimental procedure was the same as in example 5.

(3) The effect evaluation method was the same as in example 5.

(4) The results are given in the following table:

experimental example 7 human body test (effect of treatment on oral ulcer)

(1) Subjects included criteria:

a-g are the same as in Experimental example 1;

h. selecting more than 1 year with the history of oral ulcer; recurrent attacks, at least once a month; in the attack stage, and the attack time is within 48 hours; meanwhile, patients with halitosis participate in the test of the treatment effect of the toothpaste on the dental ulcer.

Subject exclusion criteria were the same as in example 1.

(2) Experimental methods

The experimental subjects participated in the human body trial test of the toothpaste, and the experimental samples were randomly grouped into 25 persons each, and the toothpastes in the examples and the comparative examples were used for each group. The oral ulcer medicament is used once in the morning and at night every day, the treatment effect of the oral ulcer is detected after the oral ulcer medicament is continuously used for 8 weeks, adverse reactions are registered, and related data are retrieved.

(3) And (3) evaluating the effect:

evaluation indexes of oral ulcer treatment effect:

total interval time (days) (interval, l): evaluation period no sum of ulcer time.

Total ulcer number (number, N): the sum of the number of ulcer recurrences over the evaluation period.

Grading evaluation indexes:

11-Total pause time extension (t test, P < 0.05)

10-Total pause time unchanged (t test, P > 0.05)

N1-Total ulcer count decreased (t test, P < 0.05)

N0-Total ulcer number unchanged (t test, P < 0.05)

Evaluation criteria:

and (3) healing: the oral ulcer can be stopped and recurred for more than one year

The effect is shown: 11N1

The method has the following advantages: 10N1 or 11N0

And (4) invalidation: 10N0

Effective rate (cure + show effect + effective)/total number of cases x 100%

(4) The results are shown in the following table:

	cure (example)	Improvement (example)	Invalid (example)	Effective rate (%)
					Comparative example 5	1	5	19	24
Comparative example 6	2	6	17	32
					Comparative example 7	0	5	20	20
Example 9	4	9	12	52
					Example 10	3	10	12	52
Example 11	5	9	11	56
					Example 12	3	8	14	44

Experimental example 8 human body test (treatment effect on oral ulcer)

(1) Subject inclusion and exclusion criteria were the same as in example 7.

(2) The experimental procedure was the same as in example 7.

(3) The effect evaluation method was the same as in example 7.

(4) The results are shown in the following table:

	cure (example)	Improvement (example)	Invalid (example)	Effective rate (%)
					Comparative example 8	3	5	17	32
Comparative example 9	5	6	14	44
					Comparative example 10	3	6	16	36
Comparative example 11	4	5	16	36
					Example 13	10	9	6	76
Example 14	12	10	3	88
					Example 15	10	11	4	84
Example 16	12	9	4	84

Although the invention has been described in detail hereinabove by way of general description, specific embodiments and experiments, it will be apparent to those skilled in the art that many modifications and improvements can be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.

Claims

1. The composition for the oral cavity is characterized by being prepared from the following active components in parts by weight:

0.1-5 parts of purple bamboo salt;

0.1-5 parts of dragon's blood extract;

0.5-5 parts by weight of latanib extract;

0.1-3 parts by weight of echinacea purpurea extract;

the sanguis Draxonis extract is water extract of sanguis Draxonis; the ratanhia extract is ratanhia root ethanol extract; the echinacea purpurea extract is an echinacea purpurea aqueous extract.

2. A composition for oral cavity is characterized in that the active components are prepared from bamboo salt, sanguis Draxonis extract, Latany extract and Echinacea purpurea extract; wherein the mass ratio of the purple bamboo salt, the dragon's blood extract, the latania extract and the echinacea extract is 1 (0.1-8) to 1-2 to 0.1-6; the sanguis Draxonis extract is water extract of sanguis Draxonis; the ratanhia extract is ratanhia root ethanol extract; the echinacea purpurea extract is an echinacea purpurea aqueous extract.

3. The composition for oral cavity of claim 2, wherein the mass ratio of the salt of black bamboo, the dragon's blood extract, the latania extract and the echinacea extract is 1 (0.1-0.5): (1.2-1.5): (0.2-0.5).

4. Use of a composition according to any one of claims 1 to 3 in the manufacture of a medicament or oral care product for reducing gingivitis, relieving toothache, removing halitosis or treating oral ulcers.

5. An oral care product comprising the composition of any one of claims 1-3; the oral care product comprises toothpaste, mouthwash, tooth powder, oral spray and oral ointment.

6. The toothpaste is characterized by comprising the following components in parts by weight:

0.1-5 parts of purple bamboo salt;

0.1-5 parts of dragon's blood extract;

0.5-5 parts by weight of latanib extract;

0.01-5 parts by weight of echinacea extract;

9-60 parts of a friction agent;

7-60 parts of a humectant;

0-5 parts by weight of a foaming agent;

0.3-6 parts of a thickening agent;

0.1-5 parts by weight of a sweetening agent;

0-3 parts of essence;

0-0.55 part by weight of a preservative;

0-5 parts by weight of an appearance modifier;

the solvent is complemented to 100 parts;

7. The toothpaste as claimed in claim 6, wherein the mass ratio of the salt of black bamboo, the dragon's blood extract, the latanib extract and the echinacea extract is 1 (0.1-0.5): 1.2-1.5): 0.2-0.5.

8. The mouthwash is characterized by comprising the following components in parts by weight:

0.1-5 parts of purple bamboo salt;

0.1-5 parts of dragon's blood extract;

0.5-5 parts by weight of latanib extract;

0.1-5 parts by weight of echinacea purpurea extract;

0-10 parts of humectant;

1-15 parts of a surfactant;

0-5 parts of thickening agent;

0-25 parts of ethanol;

0-5 parts of edible essence;

0-1 part by weight of a colorant;

the solvent is complemented to 100 parts;

9. The mouthwash of claim 8, wherein the mass ratio of the salt of black bamboo to the extract of dragon's blood, the extract of latania and the extract of echinacea is 1 (0.1-0.5) to (1.2-1.5) to (0.2-0.5).